StockNews.AI
OMCL
StockNews.AI
218 days

Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025

1. Omnicell will release Q4 and full year 2024 results on February 6, 2025. 2. A conference call will discuss these results at 8:30 a.m. ET on the same day. 3. Omnicell focuses on transforming pharmacy care through innovative solutions. 4. The company aims to improve cost savings and operational efficiency in healthcare.

6m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings reports typically have mixed investor reactions, depending on results.

How important is it?

Earnings reports provide critical insights into a company's performance and future outlook.

Why Short Term?

Earnings results could influence OMCL's stock price immediately after the release.

Related Companies

Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025

FORT WORTH, Texas--()--Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the fourth quarter and full year 2024, before market open on Thursday, February 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.

All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 2515873. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/events-and-presentations/.

About Omnicell

Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

OMCL-E

Contacts

Kathleen Nemeth
Senior Vice President, Investor Relations
ir@omnicell.com

Related News